Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L. Youssef Y, et al. Among authors: nurmemmedov e. Haematologica. 2021 Nov 1;106(11):2927-2939. doi: 10.3324/haematol.2020.268235. Haematologica. 2021. PMID: 33054136 Free PMC article.
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Yamamoto TM, et al. Among authors: nurmemmedov e. Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10. Mol Carcinog. 2019. PMID: 31219654 Free PMC article.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT. Barreyro L, et al. Among authors: nurmemmedov e. Sci Transl Med. 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9. Sci Transl Med. 2022. PMID: 35263148
WNT Signaling as a Therapeutic Target for Glioblastoma.
Latour M, Her NG, Kesari S, Nurmemmedov E. Latour M, et al. Among authors: nurmemmedov e. Int J Mol Sci. 2021 Aug 5;22(16):8428. doi: 10.3390/ijms22168428. Int J Mol Sci. 2021. PMID: 34445128 Free PMC article. Review.
Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin.
Lee KJ, Chang WL, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E, Musiyenko A, Madeira da Silva L, Annamdevula NS, Leavesley SJ, Ward A, Mattox T, Lindsey AS, Andrews J, Zhu B, Wood C, Neese A, Nguyen A, Berry K, Maxuitenko Y, Moyer MP, Nurmemmedov E, Gorman G, Coward L, Zhou G, Keeton AB, Cooper HS, Clapper ML, Piazza GA. Lee KJ, et al. Among authors: nurmemmedov e. Cancer Prev Res (Phila). 2021 Nov;14(11):995-1008. doi: 10.1158/1940-6207.CAPR-21-0208. Epub 2021 Sep 28. Cancer Prev Res (Phila). 2021. PMID: 34584001 Free PMC article.
Pritumumab, the first therapeutic antibody for glioma patients.
Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S. Babic I, et al. Among authors: nurmemmedov e. Hum Antibodies. 2018 Feb 5;26(2):95-101. doi: 10.3233/HAB-170326. Hum Antibodies. 2018. PMID: 29036806 Review.
Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, Yenugonda VM. Mukherjee A, et al. Among authors: nurmemmedov e. Hum Antibodies. 2019;27(1):53-62. doi: 10.3233/HAB-180348. Hum Antibodies. 2019. PMID: 30223393 Review.
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
Li L, Hobson L, Perry L, Clark B, Heavey S, Haider A, Sridhar A, Shaw G, Kelly J, Freeman A, Wilson I, Whitaker H, Nurmemmedov E, Oltean S, Porazinski S, Ladomery M. Li L, et al. Among authors: nurmemmedov e. Br J Cancer. 2020 Sep;123(6):1024-1032. doi: 10.1038/s41416-020-0951-2. Epub 2020 Jun 25. Br J Cancer. 2020. PMID: 32581342 Free PMC article.
31 results